 | |
 |
Cooperation Between Genome Therapeutics of US, Compugen of Israel to Develop New Generation of Drugs
From Israel's Business Arena - Globes
April 3, 2000
The cooperation will allow scientists around the world access to
information, including DNA sequence information on a large number of
microbial and fungal disease factors. Scientists hope to utilize the
information in order to understand the mechanisms by which these organisms
protect themselves from antibiotics. The knowledge gained will be used to
develop a new generation of drugs.
Genome Therapeutics is a US company, with a market value of $1 billion,
which identifies and classifies genes. The company identifies and classifies
human disease-linked genes and investigates microbial genes in order to
develop new drugs.
Compugen is an Israeli company that combines computing technology with
experimental research. The company markets its technology platform to
pharmaceutical companies and provides sophisticated scientific services to
the international scientific community through the Internet.
Published by Israel's Business Arena on April 3, 2000
|
